BR112023014247A2 - Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas - Google Patents

Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas

Info

Publication number
BR112023014247A2
BR112023014247A2 BR112023014247A BR112023014247A BR112023014247A2 BR 112023014247 A2 BR112023014247 A2 BR 112023014247A2 BR 112023014247 A BR112023014247 A BR 112023014247A BR 112023014247 A BR112023014247 A BR 112023014247A BR 112023014247 A2 BR112023014247 A2 BR 112023014247A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
breast cancer
treating breast
breast cancers
Prior art date
Application number
BR112023014247A
Other languages
English (en)
Portuguese (pt)
Inventor
James Dalton
Mitchell STEINER
Ramesh Narayanan
Sunjoo Ahn
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US20210228529A1/en
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of BR112023014247A2 publication Critical patent/BR112023014247A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112023014247A 2021-01-15 2022-01-14 Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas BR112023014247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/151,108 US20210228529A1 (en) 2012-07-13 2021-01-15 Pharmaceutical compositions for treating breast cancers and methods of uses thereof
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (1)

Publication Number Publication Date
BR112023014247A2 true BR112023014247A2 (pt) 2023-10-03

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023014247A BR112023014247A2 (pt) 2021-01-15 2022-01-14 Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas

Country Status (10)

Country Link
EP (1) EP4277613A4 (https=)
JP (1) JP2024503718A (https=)
KR (1) KR20230163362A (https=)
CN (1) CN116981451A (https=)
AU (1) AU2022208712A1 (https=)
BR (1) BR112023014247A2 (https=)
CA (1) CA3205212A1 (https=)
IL (1) IL304467A (https=)
MX (1) MX2023008375A (https=)
WO (1) WO2022155543A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (zh) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 丙酰胺类雄激素受体拮抗剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
LT2872482T (lt) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) * 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
MX389702B (es) * 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders

Also Published As

Publication number Publication date
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31
MX2023008375A (es) 2023-10-05
EP4277613A1 (en) 2023-11-22
WO2022155543A1 (en) 2022-07-21
CA3205212A1 (en) 2022-07-21
IL304467A (en) 2023-09-01
AU2022208712A9 (en) 2024-09-19
JP2024503718A (ja) 2024-01-26
EP4277613A4 (en) 2024-11-20
KR20230163362A (ko) 2023-11-30

Similar Documents

Publication Publication Date Title
BR112023014247A2 (pt) Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
ECSP10010240A (es) Tratamiento de cáncer de mama con un inhibidor de parp solo o en combinación con agentes anti-tumorales
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
PA8807801A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
AR101504A1 (es) Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
BR112023001792A2 (pt) Combinações para o tratamento de câncer
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
BR112022025105A2 (pt) Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
MX2024003989A (es) Metodos de tratamiento del cancer y composiciones farmaceuticas de los mismos.
MX2023013176A (es) Derivados espiro sustituidos.
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica